Beth Stein, MD

Articles

James F. Howard, MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

May 7th 2024

Expert neurologists share thoughts on how to improve patient/physician communication and how listening to the patient needs will aid in managing MG.

The Pharmacist’s Role in MG Management

James F. Howard, MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

May 7th 2024

Drs Howard, Silvestri, Vu, Habib, and Stein comment on the role of pharmacists in managing MG, emphasizing educating both the pharmacists and the patients.

Personalizing Care in MG

James F. Howard, MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

May 7th 2024

Expert neurologists discuss patient-focused care when it comes to treating MG, also highlighting clinical trials.

Emerging Treatments in MG

James F. Howard, MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

April 30th 2024

Neurology experts provide an overview of emerging treatments in MG, highlighting biomarkers and new routes of administration.

Treatment Adherence in MG

James F. Howard, MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

April 30th 2024

Experts in neurology discuss how to ensure disease progression in not due to poor adherence to treatment in MG, emphasizing educating the patient about their disease.

Switching MG Treatment Due to Adverse Events or Poor Disease Control

James F. Howard Jr., MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

April 23rd 2024

Expert neurologists share approaches to switching MG treatment due to either poor disease control or adverse events.

Modes of Administration for Targeted Treatment in MG

James F. Howard Jr., MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

April 23rd 2024

Experts in neurology review the varied routes of administration of targeted treatment in MG, highlighting intravenous and subcutaneous formulations and how they can provide more patient-centric care.

Use of Targeted Therapies in the Treatment Algorithm of MG

James F. Howard Jr., MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

April 16th 2024

Expert neurologists discuss the treatment algorithm of MG, focusing on the use of targeted therapies as well as barriers to their use.

Targeted Therapy Options in MG

James F. Howard, MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

April 16th 2024

Nicholas Silvestri, MD, FAAN, and Tuan Vu, MD, provide an overview of the current FDA-approved targeted therapies for the treatment of MG.

Quality of Life in MG

James F. Howard, MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

April 9th 2024

Experts in neurology highlight taking age and quality of life into consideration when approaching treatment of MG, as well as comment on the standard of care for patients.

Treatment Approach in MG

James F. Howard, MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

April 9th 2024

Expert neurologists discuss the factors that guide treatment selection in MG, shifting the framework to take patient preferences into account.

Hospitalization of Older Patients in MG

James F. Howard, MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

April 2nd 2024

Ali Habib, MD, comments on the prevalence of MG in older patients and the increasing rate of hospitalization and mortality within this group.

Accurate Diagnosis of MG

James F. Howard, MD;Nicholas J. Silvestri, MD, FAAN;Tuan Vu, MD;Ali Habib, MD;Beth Stein, MD

April 2nd 2024

Beth Stein, MD, reviews critical steps towards diagnosing MG, taking a look at the different types of reliable testing for the disease.